MFI2 (melanotransferrin) accelerates NSCLC progression by promoting cell proliferation, metastasis, and invasion through miR-107-mediated NFAT5 elevation, PI3K/AKT pathway activation, and facilitating exosome-mediated progression and pre-metastatic niche formation (50). This evidence concerns the gene NFAT5 and non-small cell lung carcinoma.